Supplements for Lp(a): The Cardiovascular Risk Mar…

Lipoprotein(a), or Lp(a), is one of the most underappreciated cardiovascular risk markers in standard medicine. Unlike LDL cholesterol, which responds meaningfully to diet and lifestyle, Lp(a) is largely genetically determined. About 20% of the population carries elevated Lp(a) above 50 mg/dL, and many of them never find out until they have a premature heart attack or stroke.

What Is Lp(a) and Why Does It Matter

Lp(a) is an LDL-like particle with an additional protein called apolipoprotein(a) attached. This extra protein makes Lp(a) more atherogenic than regular LDL in several ways: it promotes clot formation by interfering with plasminogen (the body's natural clot-dissolving system), it accumulates in arterial walls, and it promotes inflammation.

Elevated Lp(a) is an independent risk factor for coronary artery disease, aortic stenosis, and stroke. The risk is dose-dependent, and people with Lp(a) above 100 mg/dL have substantially elevated lifetime cardiovascular risk. Most guidelines now recommend measuring Lp(a) at least once in every adult's life.

Testing Lp(a) requires a specific lab order (it is not included in standard lipid panels). Testing should be done in nmol/L when possible, as this is a more accurate measure than mg/dL, which varies depending on particle size.

The Challenge: Genetics Drive Most of the Level

Roughly 70 to 90% of Lp(a) variation is genetically determined by variations in the LPA gene, which encodes apolipoprotein(a). Diet, exercise, and most lifestyle interventions have minimal impact on Lp(a) levels. This makes Lp(a) frustrating from a management standpoint but also means if your level is low, you have favorable genetics in this area.

Menopause increases Lp(a) levels by 25 to 30% in many women, which is one reason cardiovascular risk rises post-menopause beyond what LDL changes alone would explain.

Niacin: The Only Supplement with Real Evidence

Niacin (vitamin B3) at pharmacologic doses is the only supplement with consistent, replicated evidence for lowering Lp(a). Studies show extended-release niacin at 1,000 to 2,000 mg daily reduces Lp(a) by 20 to 30% on average, with some individuals seeing reductions up to 40%.

The mechanism is not fully understood but appears to involve reduced hepatic secretion of Lp(a). Unlike Lp(a)'s LDL-like fractions, which respond to LDL receptor upregulation, Lp(a) reduction by niacin seems to occur through a separate pathway.

Despite this lab effect, the AIM-HIGH and HPS2-THRIVE trials failed to show that adding niacin to statin therapy reduced cardiovascular events. This has led to some debate about whether Lp(a) lowering specifically is the mechanism or whether other benefits of niacin drive any protective effect. For patients with elevated Lp(a) who cannot access PCSK9 inhibitors, niacin remains the most evidence-based supplement option.

L-Carnitine: Modest Effects

Several studies show L-carnitine supplementation produces modest reductions in Lp(a), typically 5 to 15% reductions at doses of 2 to 3 grams daily. The effect is inconsistent across trials and appears most pronounced in people with elevated baseline Lp(a) and metabolic dysfunction.

L-carnitine transports fatty acids into mitochondria for energy production and has other cardiovascular benefits including improved post-myocardial infarction outcomes. A dose of 1 to 2 grams daily is reasonable as a low-risk addition for people with elevated Lp(a), though expectations should be modest.

Vitamin C

Some research suggests vitamin C at doses of 1,000 to 3,000 mg daily may modestly reduce Lp(a), particularly in people with lower baseline vitamin C status. The proposed mechanism involves vitamin C competing with Lp(a) in binding to arterial wall lysine residues, potentially reducing Lp(a) deposition. The evidence base is not strong, but given vitamin C's safety profile and low cost, it is a reasonable add-on.

What Actually Works: PCSK9 Inhibitors

For people with high Lp(a) who need substantial reductions, currently available PCSK9 inhibitors (evolocumab, alirocumab) reduce Lp(a) by 20 to 30%. However, like niacin, the clinical trial data has not yet confirmed that Lp(a)-specific lowering explains the cardiovascular benefit of these agents.

A new class of drugs specifically designed to lower Lp(a), including pelacarsen (an antisense oligonucleotide) and olpasiran (siRNA), are in late-stage clinical trials showing 70 to 90% Lp(a) reductions. These agents may reach clinical availability by 2026 to 2027 and will represent the first truly effective Lp(a)-lowering therapy.

Managing Risk When Lp(a) Is Elevated

Since Lp(a) cannot be dramatically lowered by most available means, risk management focuses on controlling every other modifiable risk factor aggressively. This means optimizing LDL-C (many guidelines suggest targeting LDL below 70 mg/dL for elevated Lp(a) patients), controlling blood pressure, eliminating smoking, maintaining healthy weight, and addressing insulin resistance.

Aspirin has historically been used for its antiplatelet effects to counteract Lp(a)'s prothrombotic properties, though this must be weighed against bleeding risk.

FAQ

Q: Should I get my Lp(a) tested?

Yes, at least once. The American Heart Association and European Society of Cardiology both recommend universal Lp(a) testing. It is a one-time test since levels are largely stable throughout life except for the menopause-related increase in women.

Q: If my Lp(a) is elevated, does that mean I will have heart disease?

Not necessarily. Elevated Lp(a) increases relative risk, but many people with high Lp(a) live full lives without cardiovascular events, particularly if other risk factors are well-controlled. It is a risk factor to be managed, not a sentence.

Q: How do I interpret my results?

Below 30 mg/dL (or 75 nmol/L) is low risk. 30 to 50 mg/dL is borderline. Above 50 mg/dL (125 nmol/L) represents elevated risk. Above 100 mg/dL is high risk. When in doubt, use nmol/L for more accurate risk assessment.

Track your supplements in Optimize.

Supplements for Lp(a): The Cardiovascular Risk Marker You Cannot Ignore